Document
Academic Article
RDF description of Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial - http://irises.unisr.it/resource/item/223089
Generically Dependent Continuant
Article
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Information Content Entity